{"transactions":[{"id":4638787,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-10-09T21:05:59.000Z","date":"2026-10-07","kind":"sale","planned":false,"acquired":false,"shares":1596,"price":32.06,"value":51167.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,437 of these RSUs vested on October 2, 2026. The sale reported on this\nForm 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":201532,"source":{"system":"sec-edgar","filing":"0001702969-26-000012","document":"wk-form4_1791579957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000170296926000012/wk-form4_1791579957.xml","form_type":"4"}},{"id":4638786,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-10-09T21:05:59.000Z","date":"2026-10-07","kind":"sale","planned":false,"acquired":false,"shares":2213,"price":32.06,"value":70948.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":203128,"source":{"system":"sec-edgar","filing":"0001702969-26-000012","document":"wk-form4_1791579957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000170296926000012/wk-form4_1791579957.xml","form_type":"4"}},{"id":4638781,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-10-09T21:05:05.000Z","date":"2026-10-07","kind":"sale","planned":false,"acquired":false,"shares":1327,"price":32.06,"value":42543.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 50,787 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on October 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":175218,"source":{"system":"sec-edgar","filing":"0001779707-26-000009","document":"wk-form4_1791579901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779707/000177970726000009/wk-form4_1791579901.xml","form_type":"4"}},{"id":4638778,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-10-09T21:04:08.000Z","date":"2026-10-07","kind":"sale","planned":false,"acquired":false,"shares":2241,"price":32.06,"value":71846.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on October 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 - $32.30 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":217060,"source":{"system":"sec-edgar","filing":"0001764013-26-000112","document":"wk-form4_1791579845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000112/wk-form4_1791579845.xml","form_type":"4"}},{"id":4631366,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":false,"shares":92187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The \"Service Requirement\" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The \"Performance Requirement\" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The \"Knock-in Requirement\" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."}],"balance_after":921875,"derivative":{"exercise_price":14.46,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":92187},"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4631365,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-02","kind":"sale","planned":false,"acquired":false,"shares":3506,"price":34.11,"value":119589.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":257075,"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4631364,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85886,"price":33.65,"value":2890063.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."}],"balance_after":260581,"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4631363,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-05T23:42:24.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":true,"shares":92187,"price":14.46,"value":1333024.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026."}],"balance_after":346467,"source":{"system":"sec-edgar","filing":"0001764013-26-000110","document":"wk-form4_1791243741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000110/wk-form4_1791243741.xml","form_type":"4"}},{"id":4626913,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-25T20:05:33.000Z","date":"2026-09-23","kind":"sale","planned":false,"acquired":false,"shares":2846,"price":36.36,"value":103480.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 16, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on\nSeptember 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.35 - $36.66 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":176545,"source":{"system":"sec-edgar","filing":"0001764013-26-000108","document":"wk-form4_1790366730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779707/000176401326000108/wk-form4_1790366730.xml","form_type":"4"}},{"id":673032,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-28T16:27:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":65181,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001764013-26-000103","document":"wk-form4_1787948868.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/wk-form4_1787948868.xml","form_type":"4"}},{"id":673031,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:27:50.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":43.27,"value":64905.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000103","document":"wk-form4_1787948868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/wk-form4_1787948868.xml","form_type":"4"}},{"id":673030,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T16:27:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001764013-26-000103","document":"wk-form4_1787948868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/wk-form4_1787948868.xml","form_type":"4"}},{"id":678995,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-21T20:03:52.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":3056,"price":44.16,"value":134952.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 18, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on August\n18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is\nmandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 - $44.37 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":219301,"source":{"system":"sec-edgar","filing":"0001973838-26-000007","document":"wk-form4_1787342630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000197383826000007/wk-form4_1787342630.xml","form_type":"4"}},{"id":703533,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-24T21:59:12.000Z","date":"2026-07-24","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":66681,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001643071-26-000007","document":"wk-form4_1784930349.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/wk-form4_1784930349.xml","form_type":"4"}},{"id":703532,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T21:59:12.000Z","date":"2026-07-24","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":39.8,"value":59700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001643071-26-000007","document":"wk-form4_1784930349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/wk-form4_1784930349.xml","form_type":"4"}},{"id":703531,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-24T21:59:12.000Z","date":"2026-07-24","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001643071-26-000007","document":"wk-form4_1784930349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/wk-form4_1784930349.xml","form_type":"4"}},{"id":703530,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-24T21:57:57.000Z","date":"2026-07-23","kind":"sale","planned":false,"acquired":false,"shares":6798,"price":38.69,"value":263014.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 1, 2025, the holder was granted 208,388 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on May 5, 2025, of which 13,024 of these RSUs vested on July 21, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":240798,"source":{"system":"sec-edgar","filing":"0001618670-26-000004","document":"wk-form4_1784930275.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000161867026000004/wk-form4_1784930275.xml","form_type":"4"}},{"id":703529,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-07-24T21:57:15.000Z","date":"2026-07-23","kind":"sale","planned":false,"acquired":false,"shares":2857,"price":38.69,"value":110537.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 17, 2023, the holder was granted 100,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on July 17,\n2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is\nmandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 - $39.05 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":205341,"source":{"system":"sec-edgar","filing":"0001702969-26-000010","document":"wk-form4_1784930232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000170296926000010/wk-form4_1784930232.xml","form_type":"4"}},{"id":711259,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:15:18.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":106,"price":39.99,"value":4238.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":222357,"source":{"system":"sec-edgar","filing":"0001764013-26-000083","document":"wk-form4_1783714509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000083/wk-form4_1783714509.xml","form_type":"4"}},{"id":711258,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:15:18.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":1930,"price":39.53,"value":76292.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":222463,"source":{"system":"sec-edgar","filing":"0001764013-26-000083","document":"wk-form4_1783714509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000083/wk-form4_1783714509.xml","form_type":"4"}},{"id":711212,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:13:43.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":63,"price":39.99,"value":2519.37,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 50,787 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":179391,"source":{"system":"sec-edgar","filing":"0001764013-26-000082","document":"wk-form4_1783714421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000082/wk-form4_1783714421.xml","form_type":"4"}},{"id":711211,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:13:43.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":1143,"price":39.53,"value":45182.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 50,787 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":179454,"source":{"system":"sec-edgar","filing":"0001764013-26-000082","document":"wk-form4_1783714421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000082/wk-form4_1783714421.xml","form_type":"4"}},{"id":711209,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:12:58.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":77,"price":39.99,"value":3079.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this\nForm 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":208198,"source":{"system":"sec-edgar","filing":"0001764013-26-000081","document":"wk-form4_1783714376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000081/wk-form4_1783714376.xml","form_type":"4"}},{"id":711208,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:12:58.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":1399,"price":39.53,"value":55302.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on July 2, 2026. The sale reported on this\nForm 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":208275,"source":{"system":"sec-edgar","filing":"0001764013-26-000081","document":"wk-form4_1783714376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000081/wk-form4_1783714376.xml","form_type":"4"}},{"id":711207,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:12:58.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":105,"price":39.99,"value":4198.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":209674,"source":{"system":"sec-edgar","filing":"0001764013-26-000081","document":"wk-form4_1783714376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000081/wk-form4_1783714376.xml","form_type":"4"}},{"id":711206,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:12:58.000Z","date":"2026-07-08","kind":"sale","planned":false,"acquired":false,"shares":1906,"price":39.53,"value":75344.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":209779,"source":{"system":"sec-edgar","filing":"0001764013-26-000081","document":"wk-form4_1783714376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000081/wk-form4_1783714376.xml","form_type":"4"}},{"id":715397,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":92188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The \"Service Requirement\" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The \"Performance Requirement\" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The \"Knock-in Requirement\" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."}],"balance_after":1014062,"derivative":{"exercise_price":14.46,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":92188},"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":715396,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-02","kind":"sale","planned":false,"acquired":false,"shares":3092,"price":38.48,"value":118980.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":254280,"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":715395,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86629,"price":38.14,"value":3304030.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."}],"balance_after":257372,"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":715394,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:01:25.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":92188,"price":14.46,"value":1333038.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026."}],"balance_after":344001,"source":{"system":"sec-edgar","filing":"0001764013-26-000077","document":"wk-form4_1783371682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000077/wk-form4_1783371682.xml","form_type":"4"}},{"id":725668,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:46:51.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":2966,"price":38.95,"value":115525.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.78 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":224393,"source":{"system":"sec-edgar","filing":"0001764013-26-000075","document":"wk-form4_1782517606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000075/wk-form4_1782517606.xml","form_type":"4"}},{"id":725667,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:46:51.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":14748,"price":38.18,"value":563078.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":227359,"source":{"system":"sec-edgar","filing":"0001764013-26-000075","document":"wk-form4_1782517606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000075/wk-form4_1782517606.xml","form_type":"4"}},{"id":725547,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:45:54.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":6723,"price":38.94,"value":261793.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.76 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":211685,"source":{"system":"sec-edgar","filing":"0001764013-26-000074","document":"wk-form4_1782517552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000074/wk-form4_1782517552.xml","form_type":"4"}},{"id":725546,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:45:54.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":33277,"price":38.18,"value":1270515.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 - $38.56 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":218408,"source":{"system":"sec-edgar","filing":"0001764013-26-000074","document":"wk-form4_1782517552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000074/wk-form4_1782517552.xml","form_type":"4"}},{"id":725545,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T23:45:00.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":false,"shares":17824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date."}],"balance_after":53707,"derivative":{"exercise_price":15.2,"expiration_date":"2035-04-01","underlying":"Common Stock","underlying_shares":17824},"source":{"system":"sec-edgar","filing":"0001764013-26-000073","document":"wk-form4_1782517498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000073/wk-form4_1782517498.xml","form_type":"4"}},{"id":725544,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:45:00.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":2842,"price":38.96,"value":110724.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":180597,"source":{"system":"sec-edgar","filing":"0001764013-26-000073","document":"wk-form4_1782517498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000073/wk-form4_1782517498.xml","form_type":"4"}},{"id":725543,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:45:00.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":14982,"price":38.19,"value":572162.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":183439,"source":{"system":"sec-edgar","filing":"0001764013-26-000073","document":"wk-form4_1782517498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000073/wk-form4_1782517498.xml","form_type":"4"}},{"id":725542,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:45:00.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":true,"shares":17824,"price":15.2,"value":270924.8,"ownership":{"direct":true},"balance_after":198421,"source":{"system":"sec-edgar","filing":"0001764013-26-000073","document":"wk-form4_1782517498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000073/wk-form4_1782517498.xml","form_type":"4"}},{"id":725541,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T23:44:00.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of stock options to purchase Common Shares with a grant date of May 1, 2025. The shares underlying the option vest as to 25% on April 21, 2026, with the remainder vesting in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date."}],"balance_after":283505,"derivative":{"exercise_price":15.9,"expiration_date":"2035-05-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001764013-26-000072","document":"wk-form4_1782517438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000072/wk-form4_1782517438.xml","form_type":"4"}},{"id":725540,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:44:00.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":38.46,"value":384600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 - $38.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":247596,"source":{"system":"sec-edgar","filing":"0001764013-26-000072","document":"wk-form4_1782517438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000072/wk-form4_1782517438.xml","form_type":"4"}},{"id":725539,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-26T23:44:00.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":15.9,"value":159000.0,"ownership":{"direct":true},"balance_after":257596,"source":{"system":"sec-edgar","filing":"0001764013-26-000072","document":"wk-form4_1782517438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000072/wk-form4_1782517438.xml","form_type":"4"}},{"id":725536,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T23:43:23.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":68181,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001764013-26-000071","document":"wk-form4_1782517401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000071/wk-form4_1782517401.xml","form_type":"4"}},{"id":725535,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T23:43:23.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":38.01,"value":57015.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000071","document":"wk-form4_1782517401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000071/wk-form4_1782517401.xml","form_type":"4"}},{"id":725534,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T23:43:23.000Z","date":"2026-06-26","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001764013-26-000071","document":"wk-form4_1782517401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000071/wk-form4_1782517401.xml","form_type":"4"}},{"id":730538,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:25.000Z","date":"2026-06-18","kind":"sale","planned":false,"acquired":false,"shares":2634,"price":35.39,"value":93217.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 16, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on\nJune 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."}],"balance_after":180597,"source":{"system":"sec-edgar","filing":"0001779707-26-000006","document":"wk-form4_1782158542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000177970726000006/wk-form4_1782158542.xml","form_type":"4"}},{"id":736245,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T20:03:13.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option."}],"balance_after":69681,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001764013-26-000069","document":"wk-form4_1781640191.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000069/wk-form4_1781640191.xml","form_type":"4"}},{"id":736244,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:03:13.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":34.02,"value":51030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000069","document":"wk-form4_1781640191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000069/wk-form4_1781640191.xml","form_type":"4"}},{"id":736243,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:03:13.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":8.43,"value":12645.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":118231,"source":{"system":"sec-edgar","filing":"0001764013-26-000069","document":"wk-form4_1781640191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000069/wk-form4_1781640191.xml","form_type":"4"}},{"id":758766,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":16260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2033-04-12","underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758765,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":77181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":77181},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758764,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":71492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.94,"expiration_date":"2032-01-10","underlying":"Common Stock","underlying_shares":71492},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758763,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":false,"shares":31668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.99,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":31668},"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758762,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"sale","planned":false,"acquired":false,"shares":210468,"price":33.56,"value":7063306.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":74382,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758761,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"sale","planned":false,"acquired":false,"shares":11483,"price":32.64,"value":374805.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":284850,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758760,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":16260,"price":14.7,"value":239022.0,"ownership":{"direct":true},"balance_after":296333,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758759,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":77181,"price":8.43,"value":650635.83,"ownership":{"direct":true},"balance_after":280073,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758758,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":71492,"price":7.94,"value":567646.48,"ownership":{"direct":true},"balance_after":202892,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":758757,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:04:59.000Z","date":"2026-05-28","kind":"exercise","planned":false,"acquired":true,"shares":31668,"price":4.99,"value":158023.32,"ownership":{"direct":true},"balance_after":131400,"source":{"system":"sec-edgar","filing":"0001341896-26-000004","document":"wk-form4_1780085096.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000134189626000004/wk-form4_1780085096.xml","form_type":"4"}},{"id":766275,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T20:03:32.000Z","date":"2026-05-20","kind":"sale","planned":false,"acquired":false,"shares":1698,"price":32.95,"value":55949.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 18, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on\nMay 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.55 - $33.49 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":242107,"source":{"system":"sec-edgar","filing":"0001764013-26-000067","document":"wk-form4_1779480209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000067/wk-form4_1779480209.xml","form_type":"4"}},{"id":766274,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T20:03:32.000Z","date":"2026-05-20","kind":"sale","planned":false,"acquired":false,"shares":1168,"price":32.15,"value":37551.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 18, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on\nMay 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 - $32.50 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":243805,"source":{"system":"sec-edgar","filing":"0001764013-26-000067","document":"wk-form4_1779480209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000067/wk-form4_1779480209.xml","form_type":"4"}},{"id":766273,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T20:03:32.000Z","date":"2026-05-20","kind":"sale","planned":false,"acquired":false,"shares":249,"price":30.41,"value":7572.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 18, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on\nMay 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.32 - $31.00 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":244973,"source":{"system":"sec-edgar","filing":"0001764013-26-000067","document":"wk-form4_1779480209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000067/wk-form4_1779480209.xml","form_type":"4"}},{"id":770074,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-21T01:22:04.000Z","date":"2026-05-20","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":270252,"derivative":{"exercise_price":8.43,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001643071-26-000004","document":"wk-form4_1779326521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000004/wk-form4_1779326521.xml","form_type":"4"}},{"id":770073,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T01:22:04.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":32,"value":192000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001643071-26-000004","document":"wk-form4_1779326521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000004/wk-form4_1779326521.xml","form_type":"4"}},{"id":770072,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T01:22:04.000Z","date":"2026-05-20","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":8.43,"value":50580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."}],"balance_after":122731,"source":{"system":"sec-edgar","filing":"0001643071-26-000004","document":"wk-form4_1779326521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000164307126000004/wk-form4_1779326521.xml","form_type":"4"}},{"id":795960,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":50362,"kind":"person","name":"Susman Robert Graham","position":1,"cik":"0002065992","reported_name":"Susman Robert Graham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-01T22:40:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":2502,"price":27.17,"value":67979.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":36394,"source":{"system":"sec-edgar","filing":"0001764013-26-000058","document":"wk-form4_1777675214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065992/000176401326000058/wk-form4_1777675214.xml","form_type":"4"}},{"id":801000,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-24T20:07:14.000Z","date":"2026-04-23","kind":"sale","planned":false,"acquired":false,"shares":25760,"price":29.62,"value":763011.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 1, 2025, the holder was granted 208,388 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on May 5, 2025, of which 52,097 of these RSUs vested on April 21, 2026.\nThe sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":247596,"source":{"system":"sec-edgar","filing":"0001764013-26-000056","document":"wk-form4_1777061232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000056/wk-form4_1777061232.xml","form_type":"4"}},{"id":800999,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-04-24T20:05:56.000Z","date":"2026-04-23","kind":"sale","planned":false,"acquired":false,"shares":2754,"price":29.62,"value":81573.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 17, 2023, the holder was granted 100,000 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 19, 2023, of which 6,250 of these RSUs vested on April 17,\n2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is\nmandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.23 - $30.00 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":251685,"source":{"system":"sec-edgar","filing":"0001764013-26-000055","document":"wk-form4_1777061153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000055/wk-form4_1777061153.xml","form_type":"4"}},{"id":810467,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:05:33.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":5165,"price":24.83,"value":128246.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 50,787 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 12,696 of these RSUs vested on\nApril 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":183231,"source":{"system":"sec-edgar","filing":"0001779707-26-000004","document":"wk-form4_1775851530.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000177970726000004/wk-form4_1775851530.xml","form_type":"4"}},{"id":810576,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:03:58.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":8722,"price":24.83,"value":216567.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on\nApril 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":245222,"source":{"system":"sec-edgar","filing":"0001973838-26-000004","document":"wk-form4_1775851435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000197383826000004/wk-form4_1775851435.xml","form_type":"4"}},{"id":810466,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:02:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":1518,"price":24.83,"value":37691.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on April 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":254439,"source":{"system":"sec-edgar","filing":"0001702969-26-000006","document":"wk-form4_1775851354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000170296926000006/wk-form4_1775851354.xml","form_type":"4"}},{"id":810465,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:02:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":8614,"price":24.83,"value":213885.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 1, 2025, the holder was granted 76,181 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on\nApril 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The\nsale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":255957,"source":{"system":"sec-edgar","filing":"0001702969-26-000006","document":"wk-form4_1775851354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000170296926000006/wk-form4_1775851354.xml","form_type":"4"}},{"id":811526,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":32849,"kind":"person","name":"Torti Frank","position":1,"cik":"0001647805","reported_name":"Torti Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:31:14.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":88325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the\nIssuer as of such date."}],"balance_after":88325,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":88325},"source":{"system":"sec-edgar","filing":"0001764013-26-000052","document":"wk-form4_1775766671.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000052/wk-form4_1775766671.xml","form_type":"4"}},{"id":811525,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":32849,"kind":"person","name":"Torti Frank","position":1,"cik":"0001647805","reported_name":"Torti Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:31:14.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":174189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":1009228,"source":{"system":"sec-edgar","filing":"0001764013-26-000052","document":"wk-form4_1775766671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000052/wk-form4_1775766671.xml","form_type":"4"}},{"id":811524,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:28:49.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000050","document":"wk-form4_1775766526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000050/wk-form4_1775766526.xml","form_type":"4"}},{"id":811523,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":43180,"kind":"person","name":"Fromkin Andrew J.","position":1,"cik":"0001341896","reported_name":"Fromkin Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:28:49.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":99732,"source":{"system":"sec-edgar","filing":"0001764013-26-000050","document":"wk-form4_1775766526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000050/wk-form4_1775766526.xml","form_type":"4"}},{"id":811520,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":53086,"kind":"person","name":"Hughes Douglas J.","position":1,"cik":"0001710863","reported_name":"Hughes Douglas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:26:52.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000048","document":"wk-form4_1775766410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000048/wk-form4_1775766410.xml","form_type":"4"}},{"id":811519,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":53086,"kind":"person","name":"Hughes Douglas J.","position":1,"cik":"0001710863","reported_name":"Hughes Douglas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:26:52.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":134653,"source":{"system":"sec-edgar","filing":"0001764013-26-000048","document":"wk-form4_1775766410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000048/wk-form4_1775766410.xml","form_type":"4"}},{"id":811522,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:25:16.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000046","document":"wk-form4_1775766313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000046/wk-form4_1775766313.xml","form_type":"4"}},{"id":811521,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":18745,"kind":"person","name":"Pande Atul","position":1,"cik":"0001643071","reported_name":"Pande Atul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:25:16.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":116731,"source":{"system":"sec-edgar","filing":"0001764013-26-000046","document":"wk-form4_1775766313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000046/wk-form4_1775766313.xml","form_type":"4"}},{"id":811518,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":36849,"kind":"person","name":"Bauer Jake","position":1,"cik":"0001654909","reported_name":"Bauer Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:23:54.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000044","document":"wk-form4_1775766231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000044/wk-form4_1775766231.xml","form_type":"4"}},{"id":811517,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":36849,"kind":"person","name":"Bauer Jake","position":1,"cik":"0001654909","reported_name":"Bauer Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:23:54.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":38896,"source":{"system":"sec-edgar","filing":"0001764013-26-000044","document":"wk-form4_1775766231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000044/wk-form4_1775766231.xml","form_type":"4"}},{"id":811716,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":50362,"kind":"person","name":"Susman Robert Graham","position":1,"cik":"0002065992","reported_name":"Susman Robert Graham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:22:29.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":7061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":7061,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":7061},"source":{"system":"sec-edgar","filing":"0001764013-26-000042","document":"wk-form4_1775766147.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065992/000176401326000042/wk-form4_1775766147.xml","form_type":"4"}},{"id":811715,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":50362,"kind":"person","name":"Susman Robert Graham","position":1,"cik":"0002065992","reported_name":"Susman Robert Graham","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T20:22:29.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":13880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."}],"balance_after":38896,"source":{"system":"sec-edgar","filing":"0001764013-26-000042","document":"wk-form4_1775766147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065992/000176401326000042/wk-form4_1775766147.xml","form_type":"4"}},{"id":811649,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:20:39.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":121063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":121063,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":121063},"source":{"system":"sec-edgar","filing":"0001764013-26-000040","document":"wk-form4_1775766037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000040/wk-form4_1775766037.xml","form_type":"4"}},{"id":811648,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:20:39.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":83671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":253944,"source":{"system":"sec-edgar","filing":"0001764013-26-000040","document":"wk-form4_1775766037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000040/wk-form4_1775766037.xml","form_type":"4"}},{"id":811516,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:19:05.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":96851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":96851,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":96851},"source":{"system":"sec-edgar","filing":"0001764013-26-000038","document":"wk-form4_1775765943.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000038/wk-form4_1775765943.xml","form_type":"4"}},{"id":811515,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28789,"kind":"person","name":"Stout Jay S","position":1,"cik":"0001702969","reported_name":"Stout Jay S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:19:05.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":66937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":264571,"source":{"system":"sec-edgar","filing":"0001764013-26-000038","document":"wk-form4_1775765943.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000038/wk-form4_1775765943.xml","form_type":"4"}},{"id":811514,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:17:27.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":59820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":59820,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":59820},"source":{"system":"sec-edgar","filing":"0001764013-26-000036","document":"wk-form4_1775765844.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000036/wk-form4_1775765844.xml","form_type":"4"}},{"id":811513,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:17:27.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":41343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":188396,"source":{"system":"sec-edgar","filing":"0001764013-26-000036","document":"wk-form4_1775765844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000036/wk-form4_1775765844.xml","form_type":"4"}},{"id":811532,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:13:44.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":336043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":336043,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":336043},"source":{"system":"sec-edgar","filing":"0001764013-26-000034","document":"wk-form4_1775765620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000034/wk-form4_1775765620.xml","form_type":"4"}},{"id":811531,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:13:44.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":232252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":251813,"source":{"system":"sec-edgar","filing":"0001764013-26-000034","document":"wk-form4_1775765620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000034/wk-form4_1775765620.xml","form_type":"4"}},{"id":811512,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-09T20:10:31.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":94002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":94002,"derivative":{"exercise_price":24.61,"expiration_date":"2036-04-07","underlying":"Common Stock","underlying_shares":94002},"source":{"system":"sec-edgar","filing":"0001764013-26-000032","document":"wk-form4_1775765429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000032/wk-form4_1775765429.xml","form_type":"4"}},{"id":811511,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":28790,"kind":"person","name":"Girao Tiago","position":1,"cik":"0001618670","reported_name":"Girao Tiago","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:10:31.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":64968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units (\"RSUs\") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date."}],"balance_after":273356,"source":{"system":"sec-edgar","filing":"0001764013-26-000032","document":"wk-form4_1775765429.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000032/wk-form4_1775765429.xml","form_type":"4"}},{"id":816574,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":368750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The \"Service Requirement\" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The \"Performance Requirement\" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The \"Knock-in Requirement\" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."}],"balance_after":1106250,"derivative":{"exercise_price":14.46,"expiration_date":"2030-04-01","underlying":"Common Stock","underlying_shares":368750},"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816573,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":1409,"price":24.6,"value":34661.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 - $24.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":19561,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816572,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-02","kind":"sale","planned":false,"acquired":false,"shares":12820,"price":24.04,"value":308192.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 - $24.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":20970,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816571,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":334960,"price":25.1,"value":8407496.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."}],"balance_after":33790,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":816570,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:33:01.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":368750,"price":14.46,"value":5332125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2025, the Reporting Person was granted capped value appreciation rights (\"CVARs\"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the \"CVAR Amount\"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026."}],"balance_after":368750,"source":{"system":"sec-edgar","filing":"0001764013-26-000024","document":"wk-form4_1775248378.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000176401326000024/wk-form4_1775248378.xml","form_type":"4"}},{"id":832396,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":30999,"kind":"person","name":"Van Tuyl Christopher","position":1,"cik":"0001779707","reported_name":"Van Tuyl Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-20T20:11:19.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":2877,"price":24.97,"value":71838.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 16, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on\nMarch 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.\nThe sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."}],"balance_after":147053,"source":{"system":"sec-edgar","filing":"0001764013-26-000015","document":"wk-form4_1774037475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000015/wk-form4_1774037475.xml","form_type":"4"}},{"id":877581,"issuer":{"id":3632,"kind":"organization","name":"Immunovant, Inc.","symbol":"IMVT"},"owners":[{"id":20900,"kind":"person","name":"Gloria Melanie","position":1,"cik":"0001973838","reported_name":"Gloria Melanie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-27T21:07:42.000Z","date":"2026-02-25","kind":"sale","planned":false,"acquired":false,"shares":942,"price":28.9,"value":27223.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 18, 2024, the holder was granted 109,956 restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on November 20, 2024, of which 6,872 of these RSUs vested on\nFebruary 18, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.\nThe sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the\nReporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 - $29.13 per share, inclusive. The Reporting Person undertakes to provide\nto the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nrange set forth in this footnote to this Form 4."}],"balance_after":170273,"source":{"system":"sec-edgar","filing":"0001764013-26-000013","document":"wk-form4_1772226458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1973838/000176401326000013/wk-form4_1772226458.xml","form_type":"4"}}],"next_cursor":"2026-02-27T21:07:42.000000Z,877581"}